Original StudyPrimary Tumor Resection and Overall Survival in Patients With Metastatic Colorectal Cancer Treated With Palliative Intent
Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancer mortality worldwide.1 The overall survival (OS) of patients with metastatic CRC (mCRC) treated with palliative intent has continued to improve with the advent of modern cytotoxic drugs and biologic therapies.2 In the absence of data from prospective randomized trials, the optimal approach to the management of the primary tumor continues to be debated.
Multiple series have reported that primary tumor resection (PTR) at diagnosis is associated with improved survival outcomes.3, 4, 5 These retrospective series have often been limited by the lack of data on known major prognostic factors. The reported OS differences have often been substantial, including a recent population-based cohort6 that reported PTR improved the median OS from 7.9 to up to 17.9 months (hazard ratio [HR], 0.56; P = .0007). Faron et al7 also analyzed individual data from patients with mCRC enrolled in first-line chemotherapy trials and reported improved outcomes with PTR, adjusting for multiple prognostic variables.
However, many have questioned the true survival impact of PTR at diagnosis, arguing that the reported benefits likely reflect that patients selected for PTR had more favorable prognostic features. Further concerns include that operative complications can be significant8 and that, for some patients, PTR could delay administration of systemic therapy to the extent that the treatment would be less effective or could not be safely delivered.9 When patients do not undergo PTR at diagnosis, the rates of intestinal complications resulting from the intact primary tumor appear to be very low,10, 11 including a prospective series10 in which the expected OS outcomes for patients with mCRC were achieved.
The present study reports on data from a comprehensive mCRC registry that prospectively captures information on consecutive patients treated in routine clinical practice. The unique aspects of the data set included mandatory and prospective clinician documentation at point of care for: (1) the treatment intent; (2) known major prognostic factors, including documentation of the Eastern Cooperative Oncology Group performance status (ECOG PS) and the Charlson comorbidity index; (3) the primary tumor site; and (4) comprehensive data on further management (including any systemic therapy and later PTR). These aspects allowed researchers to address recurrent limitations of previous retrospective analyses.
Section snippets
Participants and Setting
The present analyses were conducted using data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry, which began in mid-2009 and is ongoing. Data were contributed from 10 private and 13 public hospitals across Australia. The human research ethics committee at each participating hospital approved the study.
TRACC is a clinician-led registry, established with support from Roche Australia.12 Point of care data are entered into an electronic database by clinicians, and key
Patient and Disease Characteristics
Of a total of 1567 patients with mCRC, after excluding patients defined by the treating clinician as having resectable or potentially resectable metastatic disease, 1063 patients (690 with de novo and 373 with metachronous disease) treated with palliative intent were identified. The median follow-up period for all patients with mCRC treated with palliative intent was 30 months.
A total of 20 patients with metachronous disease and a primary site classified as ‘colon NOS’ were excluded during the
Discussion
The optimal management of the primary tumor in patients with de novo mCRC treated with palliative intent remains a clinical dilemma. The inconclusive data in published studies regarding the effect of PTR on OS are likely explained by the retrospective nature of previous studies, the varying definitions of de novo versus metachronous mCRC,16, 17 inconsistent definitions of PTR at diagnosis versus no PTR, and the different patient populations and time periods examined. A recurrent issue in most
Conclusion
We were unable to demonstrate a significant survival gain in association with PTR at diagnosis, after adjusting for major known prognostic variables. The results from the present study are relevant because our patients had access to modern systemic therapies, including cytotoxic chemotherapy, bevacizumab, and EGFR inhibitors. The observed incidence of later PTR was low, in particular, for patients with a primary colon cancer, suggesting that PTR later in the clinical course applies to a limited
Disclosure
H.L. Wong, K.M. Field, S. Kosmider, J. Tie, R. Wong, J. Shapiro, L. Nott, G. Richardson, P. Cooray, and P. Gibbs have received research funding for the study database through Roche Products Pty Limited.
Acknowledgments
Roche Products Pty Limited provided financial assistance for the development and the maintenance of this clinical registry.
References (26)
- et al.
Primary tumour resection and survival in the palliative management of metastatic colorectal cancer
Eur J Surg Oncol
(2009) - et al.
Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials
Eur J Cancer
(2015) - et al.
Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases
Ann Oncol
(2008) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Federation Francophone de Cancerologie Digestive 9601
Eur J Cancer
(2013) - et al.
Primary tumour resection in patients with metastatic colorectal cancer is associated with reversal of systemic inflammation and improved survival
Clin Colorectal Cancer
(2015) - et al.
Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in the Netherlands, 1989-2006
Ann Oncol
(2010) - et al.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Int J Cancer
(2015) - et al.
Metastatic colorectal cancer: current treatment and future options for improved survival: medical approach—present status
Scand J Gastroenterol
(2012) - et al.
First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases
Arch Surg
(2008)
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature
Ann Surg Oncol
Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients
Ann Surg Oncol
Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases
Br J Surg
Cited by (11)
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2022, European Journal of Surgical OncologyCitation Excerpt :A number of large pooled retrospective studies report similar benefits with UPTR [4–6]. Nonetheless, other studies that captured the intent of surgery and adjusted for confounder effects, failed to report a beneficial effect of UPTR [7,8]. Furthermore, a prospective randomised controlled study in Japan in asymptomatic unresectable stage IV CRC patients was recently terminated prematurely after an interim analysis failed to show a difference in survival when UPTR was performed prior to treatment with bevacizumab-based chemotherapy [9].